Skip to main content
. Author manuscript; available in PMC: 2013 Jul 1.
Published in final edited form as: J Allergy Clin Immunol. 2012 Apr 21;130(1):195–204.e9. doi: 10.1016/j.jaci.2012.02.042

FIG 5. Proposed mechanisms of Imidazoquinoline TLR8 agonist activation of human newborn monocytes and DCs via adenosine-refractory and caspase-1-dependent pathways.

FIG 5

3M-002 agonists are refractory to inhibitory effects of the adenosine/cAMP pathway, which skews neonatal immunity against Th1-polarizition (A), can overcome impaired IL-1β responses of neonatal DCs to LPS/ATP (B) independently of exogenous ATP (C).